Introduction {#section5-1470320316656679}
============

The renin--angiotensin system (RAS) is a key therapeutic target for diabetes mellitus, chronic kidney disorders, hypertension, heart problems, chronic obstructive pulmonary disease and stroke. RAS blockers include angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs). The impacts of RAS blockade on the incidence and mortality of cancer remain debated. Some studies suggest that the use of ACEIs and ARBs may increase the risk of cancer.^[@bibr1-1470320316656679]^ A meta-analysis showed an increased risk of cancer by ARBs compared with controlled therapy.^[@bibr2-1470320316656679]^ Intriguingly, the US Food and Drug Administration claims no increase in the risk of cancer with ARBs.^[@bibr3-1470320316656679]^

Angiotensin II and angiotensin II type 1 receptors (AT1) play major roles in the development and progression of cancer.^[@bibr4-1470320316656679],[@bibr5-1470320316656679]^ Angiotensin II acts on the AT1 receptor to promote cell proliferation and angiogenesis.^[@bibr6-1470320316656679][@bibr7-1470320316656679]--[@bibr8-1470320316656679]^ The expression of AT1 receptors has been reported to be upregulated in hyperplasic and cancer tissues.^[@bibr9-1470320316656679],[@bibr10-1470320316656679]^ ACEIs prevent the generation of angiotensin II by inhibiting angiotensin-converting enzymes (ACEs) while ARBs selectively block angiotensin II binding to the AT1 receptor. These actions may have important implications for cancer development. However, the existing clinical evidence is inconsistent.^[@bibr2-1470320316656679],[@bibr11-1470320316656679],[@bibr12-1470320316656679]^ Therefore we conducted a systematic review and meta-analysis to evaluate the impact of an RAS blockade with ACEI/ARB therapy on the risk of cancer and death.

Materials and methods {#section6-1470320316656679}
=====================

Search strategy {#section7-1470320316656679}
---------------

Candidate studies were identified through electronic literature searches of PubMed, Cochrane Library databases, Chinese National Knowledge Infrastructure (CNKI) and Wanfang databases from 1960 to August 2015. We used the following MeSH terms and keywords: 'cancer', 'carcinoma', 'sarcoma', 'neoplasia' or 'malignancy' in combination with 'renin--angiotensin system', 'RAS' and 'angiotensin-receptor blocker', 'ARB' or 'angiotensin-converting enzyme inhibitor', 'ACEI'. A manual search of reference lists from reports of review articles, meta-analyses and original studies was performed to identify additional relevant studies.

Selection criteria {#section8-1470320316656679}
------------------

Our inclusion criteria were as follows: (a) clinical trials, including randomised controlled trials (RCTs), cohort studies and case--control studies; (b) use of ACEIs and/or ARBs in the participants; (c) incidence and/or mortality due to cancer as an outcome with detailed description of relative risk ratios (RRs), corresponding 95% confidence intervals (CIs), size of the baseline samples and years of follow-up; and (d) each study should have enrolled at least 200 participants. Literature meeting any of the following criteria was excluded: non-clinical nature, non-human studies, duplication, unclear outcome evaluation and non-original studies including reviews, letters, editorials and commentaries.

Data extraction {#section9-1470320316656679}
---------------

The extracted data included first author name, study title, year of publication date, country of origin, disease, demographic characteristics of participants, details of intervention, outcome measurements, intervention durations, incidence and mortality of cancer and RR for cancer with the corresponding 95% CI. All articles were read by two independent reviewers (JS and XZ) who extracted data from the articles according to a standardised data extraction form. Disagreements were resolved in all cases by discussion among our team members.

Quality assessment {#section10-1470320316656679}
------------------

The methodological quality of studies was assessed by the Newcastle--Ottawa scale (NOS). Using the NOS, a study is judged on three broad perspectives: the selection of the study groups, the comparability of the groups and the ascertainment of the outcome of interest.^[@bibr13-1470320316656679]^ Studies with a score of less than 3 were considered as low quality, while scores of 4--6 were considered as moderate quality and 7--9 were considered as high quality. All studies were reviewed by two investigators (JS and X-NS). A third reviewer (H-LZ) served to resolve disputes.

Statistical analyses {#section11-1470320316656679}
--------------------

This study is reported in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement.^[@bibr14-1470320316656679]^ Dichotomous outcome data from individual trials were analysed by using RR and corresponding 95% CI. Data were pooled using the random effects model or fixed effect model according to the heterogeneity between studies. Heterogeneity was assessed using the chi-square test, with values greater than 50% regarded as being indicative of moderate to high heterogeneity. For studies of moderate to high heterogeneity, a random effects meta-analysis model was used;^[@bibr15-1470320316656679]^ otherwise, we used the fixed effects meta-analysis model.^[@bibr16-1470320316656679]^ The possibility of publication bias was quantified using the Begg's and Egger's test.^[@bibr17-1470320316656679],[@bibr18-1470320316656679]^ A two-tailed *P*\>0.050 was considered to be no publication bias, followed by confirmation using the visual inspection of Begg funnel plots in which relative risks were plotted against their standard errors (SE). All the analyses were carried out using Stata 11.0SE statistical software package (StataCorp, College Station, TX, USA).

Results {#section12-1470320316656679}
=======

Study description {#section13-1470320316656679}
-----------------

[Figure 1](#fig1-1470320316656679){ref-type="fig"} shows the study selection process. A total of 31 studies met our inclusion criteria and involved 3,957,725 participants with hypertension, cardiomyopathy, vascular disease, breast cancer, colon cancer, lung cancer, melanoma, type 2 diabetes mellitus and glomerulonephritis. The age of the participants ranged from 18 to 80 years. All the studies were published between 1998 and 2014 ([Table 1](#table1-1470320316656679){ref-type="table"}). There were 17 observational studies and 14 RCTs. Seven studies tested dual blockade with ARBs and ACEIs, 24 studies assessed ARB monotherapy and eight studies focused on ACEI monotherapy. The duration of follow-up ranged from 1.9 to 7.8 years. Sites (number) of the studies were as follows: America (13),^[@bibr19-1470320316656679][@bibr20-1470320316656679][@bibr21-1470320316656679][@bibr22-1470320316656679][@bibr23-1470320316656679][@bibr24-1470320316656679][@bibr25-1470320316656679][@bibr26-1470320316656679][@bibr27-1470320316656679][@bibr28-1470320316656679][@bibr29-1470320316656679][@bibr30-1470320316656679]--[@bibr31-1470320316656679]^ England (5),^[@bibr11-1470320316656679],[@bibr32-1470320316656679][@bibr33-1470320316656679][@bibr34-1470320316656679]--[@bibr35-1470320316656679]^ Taiwan (4),^[@bibr12-1470320316656679],[@bibr36-1470320316656679][@bibr37-1470320316656679]--[@bibr38-1470320316656679]^ Denmark (2),^[@bibr39-1470320316656679],[@bibr40-1470320316656679]^ Sweden (2),^[@bibr41-1470320316656679],[@bibr42-1470320316656679]^ Netherlands (1),^[@bibr43-1470320316656679]^ Japan (1),^[@bibr44-1470320316656679]^ Canada (1),^[@bibr45-1470320316656679]^ Norway (1)^[@bibr46-1470320316656679]^ and South Korea (1).^[@bibr47-1470320316656679]^ [Table 1](#table1-1470320316656679){ref-type="table"} shows the characteristics of the 31 studies included in the meta-analysis.

![Flow chart of selection process in this study.](10.1177_1470320316656679-fig1){#fig1-1470320316656679}

###### 

Summary of the characteristics of the included trials.

![](10.1177_1470320316656679-table1)

  First author, year                                   Study type              Country       Type of cancer                       Age (year)   Participants   Intervention   Cancer outcome   Follow-up (years)
  ---------------------------------------------------- ----------------------- ------------- ------------------------------------ ------------ -------------- -------------- ---------------- -------------------
  Makar et al.,^[@bibr19-1470320316656679]^ 2014       Observational studies   USA           Colorectal cancer                    70           31,086         ARB, ACEI      Incidence        ⩾5.0
  Engineer et al.,^[@bibr22-1470320316656679]^ 2013    Observational studies   USA           Colorectal cancer                    65           262            ARB, ACEI      Mortality        2.9
  Cardwell et al.,^[@bibr32-1470320316656679]^ 2014    Observational studies   UK            Breast cancer                        65           16,920         ARB, ACEI      Mortality        3.9
  Colorectal cancer                                    65                      12,053        ARB, ACEI                            Mortality    2.8                                            
  Prostate cancer                                      65                      12,188        ARB, ACEI                            Mortality    3.8                                            
  Rao et al.,^[@bibr21-1470320316656679]^ 2013         Observational studies   USA           Lung cancer                          62           1,228,960      ARB            Incidence        4.5
  Rao et al.,^[@bibr20-1470320316656679]^ 2013         Observational studies   USA           Prostate cancer                      65           543,824        ARB            Incidence        6.0
  Koomen et al.,^[@bibr43-1470320316656679]^ 2009      Observational studies   Netherlands   Melanoma                             67           6520           ARB            Incidence        2.7
  Chae et al.,^[@bibr23-1470320316656679]^ 2011        Observational studies   USA           Breast cancer                        59           703            ACEI           Incidence        4.6
  Chiang et al.,^[@bibr36-1470320316656679]^ 2014      Observational studies   Taiwan        Hypertension                         59           69,660         ACEI           Incidence        2.4
  Sugiura et al.,^[@bibr44-1470320316656679]^ 2012     Randomised trials       Japan         Hypertension                         65           2049           ARB            Incidence        4.2
  Mortality                                                                                                                                                                                   
  Bhaskaran et al.,^[@bibr11-1470320316656679]^ 2012   Observational studies   UK            Hypertension                         64           377,649        ARB            Incidence        4.6
  Julius et al.,^[@bibr26-1470320316656679]^ 2006      Randomised trials       USA           Hypertension                         48           772            ARB            Incidence        3.6
  Julius et al.,^[@bibr27-1470320316656679]^ 2004      Randomised trials       USA           Hypertension                         67           15,245         ARB            Incidence        4.2
  Huang et al.,^[@bibr12-1470320316656679]^ 2011       Observational studies   Taiwan        Hypertension                         59           109,002        ARB            Incidence        5.7
  Dahlof et al.,^[@bibr41-1470320316656679]^ 2002      Randomised trials       Sweden        Hypertension                         67           9193           ARB            Incidence        4.8
  Lindholm et al.,^[@bibr42-1470320316656679]^ 2001    Randomised trials       Sweden        Hypertension                         76           6614           ACEI           Incidence        5.0
  Lewis et al.,^[@bibr29-1470320316656679]^ 2001       Randomised trials       USA           Hypertension                         59           1715           ARB            Incidence        2.6
  Lever et al.,^[@bibr35-1470320316656679]^ 1998       Observational studies   UK            Hypertension                         52           5207           ACEI           Incidence        6.6
  NAVIGATOR^[@bibr24-1470320316656679]^ 2010           Randomised trials       USA           Cardiovascular disease               64           9306           ARB            Incidence        5.0
  ONTARGET^[@bibr25-1470320316656679]^ 2008            Randomised trials       USA           Cardiovascular disease               66           23,994         ARB            Incidence        4.7
  ARB+ACEI                                                                                                                                                                                    
  TRANSCEND^[@bibr34-1470320316656679]^, 2008          Randomised trials       UK            Cardiovascular disease               67           5926           ARB            Incidence        4.7
  Yusuf et al.,^[@bibr45-1470320316656679]^ 2008       Randomised trials       Canada        Cardiovascular disease               66           20,332         ARB            Incidence        2.5
  ARB+ACEI                                                                                                                                                                                    
  Massie et al.,^[@bibr31-1470320316656679]^ 2008      Randomised trials       USA           Cardiovascular disease               72           4128           ARB            Incidence        4.1
  ARB+ACEI                                                                                                                                                                                    
  Pfeffer et al.,^[@bibr28-1470320316656679]^ 2003     Randomised trials       USA           Cardiovascular disease               65           14,703         ARB            Incidence        2.1
  ARB+ACEI                                                                                                                                                                                    
  Dickstein et al.,^[@bibr46-1470320316656679]^ 2002   Randomissed trials      Norway        Cardiovascular disease               67           5477           ARB            Mortality        2.7
  Cohn et al.,^[@bibr30-1470320316656679]^ 2001        Randomised trials       USA           Cardiovascular disease               63           5010                          Incidence        1.9
  ARB+ACEI                                                                                                                                                                                    
  Chin et al.,^[@bibr47-1470320316656679]^ 2011        Observational studies   South Korea   Glomerulonephritis                   41           3288           ARB            Incidence        2.5
  Mortality                                                                                                                                                                                   
  Chang et al.,^[@bibr38-1470320316656679]^ 2011       Observational studies   Taiwan        Type 2 diabetes mellitus             66           5104           ARB            Incidence        7.4
  Wang et al.,^[@bibr37-1470320316656679]^ 2013        Observational studies   Taiwan        Breast, colon, lung, rectum cancer   62           85,842         ARB            Incidence        4.8
  Azoulay et al.,^[@bibr33-1470320316656679]^ 2012     Observational studies   UK            Breast, colon, lung, rectum cancer   72           410,167        ARB            Incidence        6.4
  Hallas et al.,^[@bibr39-1470320316656679]^ 2012      Observational studies   Denmark       Breast, colon, lung, rectum cancer   69           597,668        ARB, ACEI      Incidence        7.8
  Pasternak et al.,^[@bibr40-1470320316656679]^ 2011   Observational studies   Denmark       Breast, colon, lung, rectum cancer   63           317,158        ARB, ACEI      Incidence        2.9

ARB: angiotensin II type 1 receptor blocker; ACEI: angiotensin-converting enzyme inhibitor.

Risk of bias within studies {#section14-1470320316656679}
---------------------------

As shown in [Table 2](#table2-1470320316656679){ref-type="table"}, the range in the total NOS score for the 31 studies was 6 to 9 (theoretical range 0 to 9) and the mean (SD) was 7.7 (0.77). No publication bias was evident by Begg's test (*P*=0.160) and Egger's test (*P*=0.790). Consistently, all the funnel plots were symmetric, indicating no publication bias ([Figure 2](#fig2-1470320316656679){ref-type="fig"}).

###### 

Quality assessment of the 31 studies.

![](10.1177_1470320316656679-table2)

  Authors                                        Year   Selection score   Comparability score   Outcome score   Total score
  ---------------------------------------------- ------ ----------------- --------------------- --------------- -------------
  Makar et al.^[@bibr19-1470320316656679]^       2014   4                 2                     2               8
  Chiang et al.^[@bibr36-1470320316656679]^      2014   4                 2                     2               8
  Cardwell et al.^[@bibr32-1470320316656679]^    2014   3                 2                     2               7
  Rao et al.^[@bibr21-1470320316656679]^         2013   3                 2                     3               8
  Rao et al.^[@bibr20-1470320316656679]^         2013   3                 2                     3               8
  Wang et al.^[@bibr37-1470320316656679]^        2013   4                 1                     2               7
  Engineer et al.^[@bibr22-1470320316656679]^    2013   3                 1                     2               6
  Sugiura et al.^[@bibr44-1470320316656679]^     2012   3                 2                     2               7
  Bhaskaran et al.^[@bibr11-1470320316656679]^   2012   4                 2                     3               9
  Azoulay et al.^[@bibr33-1470320316656679]^     2012   4                 2                     2               8
  Hallas et al.^[@bibr39-1470320316656679]^      2012   4                 0                     2               6
  Pasternak et al.^[@bibr40-1470320316656679]^   2011   4                 2                     2               8
  Chae et al.^[@bibr23-1470320316656679]^        2011   3                 2                     2               7
  Huang et al.^[@bibr12-1470320316656679]^       2011   4                 2                     3               9
  Chin et al.^[@bibr47-1470320316656679]^        2011   3                 2                     2               7
  Chang et al.^[@bibr38-1470320316656679]^       2011   4                 2                     3               9
  NAVIGATOR^[@bibr24-1470320316656679]^          2010   4                 2                     2               8
  Koomen et al.^[@bibr43-1470320316656679]^      2009   3                 1                     2               6
  ONTARGET^[@bibr25-1470320316656679]^           2008   4                 2                     3               9
  TRANSCEND^[@bibr34-1470320316656679]^          2008   4                 2                     3               9
  Yusuf et al.^[@bibr45-1470320316656679]^       2008   4                 2                     2               8
  Massie et al.^[@bibr31-1470320316656679]^      2008   4                 2                     3               9
  Julius et al.^[@bibr26-1470320316656679]^      2006   4                 2                     2               8
  Julius et al.^[@bibr27-1470320316656679]^      2004   4                 2                     2               8
  Pfeffer et al.^[@bibr28-1470320316656679]^     2003   3                 2                     3               8
  Dahlof et al.^[@bibr41-1470320316656679]^      2002   3                 2                     2               7
  Dickstein et al.^[@bibr46-1470320316656679]^   2002   4                 2                     2               8
  Lindholm et al.^[@bibr42-1470320316656679]^    2001   3                 2                     2               7
  Lewis et al.^[@bibr29-1470320316656679]^       2001   4                 1                     2               7
  Cohn et al.^[@bibr30-1470320316656679]^        2001   4                 2                     2               8
  Lever et al.^[@bibr35-1470320316656679]^       1998   4                 1                     2               7

![Funnel plots for assessing publication bias.](10.1177_1470320316656679-fig2){#fig2-1470320316656679}

Outcomes {#section15-1470320316656679}
--------

### RAS blockade on incidence of cancer {#section16-1470320316656679}

There were 28 studies reporting the incidence of cancer ([Table 1](#table1-1470320316656679){ref-type="table"}). [Figure 3](#fig3-1470320316656679){ref-type="fig"} shows incidence reduction with ARB/ACEI in the observational studies (RR 0.82, 95% CI 0.73--0.93, *P*=0.001). In the RCTs, incidence reduction with ARB/ACEI was not significant (RR 1.00, 95% CI 0.92--1.08, *P*=0.989).

![Incidence reduction with angiotensin-converting enzyme inhibitor/angiotensin II type 1 receptor blocker therapy in randomised controlled trials and observational studies.](10.1177_1470320316656679-fig3){#fig3-1470320316656679}

In subgroup analysis by RAS blockers, ACEIs (RR 0.84, 95% CI 0.72--0.99, *P*=0.033) and ARBs (RR 0.91, 95% CI 0.84--0.99, *P*=0.022) consistently lowered the incidence of cancer in the observational studies ([Figure 4](#fig4-1470320316656679){ref-type="fig"}). In the RCTs, no benefits were evident by ARBs (RR 1.00, 95% CI 0.92--1.10, *P*=0.964) or by combined therapy of ARBs and ACEIs (RR 1.05, 95% CI 0.87--1.27, *P*=0.603).

![Subgroup analyses of monotherapy with angiotensin-converting enzyme inhibitor/angiotensin II type 1 receptor blocker therapy and dual renin--angiotensin system blockade.](10.1177_1470320316656679-fig4){#fig4-1470320316656679}

[Figure 5](#fig5-1470320316656679){ref-type="fig"} illustrates the pooled data of the observational studies and RCTs stratified by sites of cancer. The observational studies revealed significant incidence reduction with ARB/ACEI in lung cancer (RR 0.85, 95% CI 0.75--0.97, *P*=0.015) but not colorectal cancer (*P*=0.164), breast cancer (*P*=0.211) or prostate cancer (*P*=0.506). The RCTs showed no incidence reduction with ACEI/ARB in lung cancer, breast cancer or prostate cancer.

![Incidence reduction with angiotensin-converting enzyme inhibitor/angiotensin II type 1 receptor blocker therapy in site-specific cancer.](10.1177_1470320316656679-fig5){#fig5-1470320316656679}

Although the pooled data of 28 studies in total disclosed significant incidence reduction with the RAS blockade ([Figure 6(a)](#fig6-1470320316656679){ref-type="fig"}), the protective effects were not statistically significant with the duration of follow-up stratified into less than 3, 3--5 and over 5 years. [Figure 6(b)](#fig6-1470320316656679){ref-type="fig"} demonstrates a trend of reduced RR along with the time of follow-up.

![Incidence reduction with angiotensin-converting enzyme inhibitor/angiotensin II type 1 receptor blocker therapy stratified by the duration of follow-up. (a) Forest plot; (b) Relative risk ratios.](10.1177_1470320316656679-fig6){#fig6-1470320316656679}

### RAS blockade on mortality of cancer {#section17-1470320316656679}

[Figure 7](#fig7-1470320316656679){ref-type="fig"} shows mortality reduction with ARB/ACEI in the observational studies (RR 0.71, 95% CI 0.55--0.93, *P*=0.051). In the RCTs, mortality reduction was not significant (RR 0.99, 95% CI 0.89--1.09, *P*=0.765).

![Mortality reduction with angiotensin-converting enzyme inhibitor/angiotensin II type 1 receptor blocker therapy in observational studies and randomised controlled trials.](10.1177_1470320316656679-fig7){#fig7-1470320316656679}

### Differences in outcomes for cancer in observational studies and RCTs {#section18-1470320316656679}

Differences in the observational studies and RCTs included duration of follow-up and sample sizes ([Table 3](#table3-1470320316656679){ref-type="table"}). The range of follow-up duration in observational studies was 2.4--7.8 years, compared to 1.9--5.0 years in RCTs. The mean duration of follow-up was 23% higher in observational studies than in RCTs. Moreover, the 17 observational studies had a sample size much larger than the 14 RCTs. The observational studies included 289,858 RAS blockade users and 3,833,261 participants, compared with 59,802 and 124,464, respectively, for the RCTs.

###### 

Differences in observational studies and randomised controlled trials (RCTs) included in this meta-analysis.

![](10.1177_1470320316656679-table3)

                            Observational studies   RCTs
  ------------------------- ----------------------- ---------------
  Study included            17                      14
  Follow up (mean, years)   4.59 (2.4--7.8)         3.72 (1.9--5)
  User                      289,858                 59,802
  Participant               3,833,261               124,464
  ACEI                      3                       1
  ARB                       9                       12
  ARB+ACEI                  0                       5
  ARB or ACEI               5                       0

ARB: angiotensin II type 1 receptor blocker; ACEI: angiotensin-converting enzyme inhibitor.

Discussion {#section19-1470320316656679}
==========

This meta-analysis reveals that the significant benefits of the RAS blockade observed in case--control studies and cohort studies might diminish in RCTs. Monotherapy with ACEI/ARB might have protective effects on the incidence and mortality of cancer in the pooled analysis of observational studies. The claimed therapeutic benefits in observational studies could not be validated in RCTs. The observed benefits of RAS blockade against the risk of cancer and death could largely result from non-randomised clinical design with a prolonged period of follow-up.

Observational studies have shown that ACEI/ARB may reduce the incidence and mortality of cancer. Angiotensin II receptors AT1 and AT2 are widely distributed in the cardiovascular system, brain, liver, kidney, adrenal cortex, muscle and connective tissue.^[@bibr48-1470320316656679],[@bibr49-1470320316656679]^ Angiotensin II, the known key active peptide of RAS, binds the AT1 receptor to promote the initiation and progression of cancer by stimulating cell proliferation, angiogenesis and inflammation^[@bibr50-1470320316656679][@bibr51-1470320316656679][@bibr52-1470320316656679]--[@bibr53-1470320316656679]^ ([Figure 8](#fig8-1470320316656679){ref-type="fig"}). The network regulation may explain the decreased risk of cancer incidence and mortality with RAS blockade.^[@bibr54-1470320316656679][@bibr55-1470320316656679]--[@bibr56-1470320316656679]^ Cancer cells are angiogenesis dependent, and thus blockade of angiogenesis could limit tumour growth.^[@bibr57-1470320316656679][@bibr58-1470320316656679][@bibr59-1470320316656679]--[@bibr60-1470320316656679]^ Indeed, several studies have shown angiotensin II in the promotion of angiogenesis due to increased vascular endothelial growth factor expression by activation of the AT1.^[@bibr61-1470320316656679][@bibr62-1470320316656679]--[@bibr63-1470320316656679]^ In contrast to angiotensin II, the angiotensin-(1-7) inhibits both angiogenesis and cell proliferation.^[@bibr64-1470320316656679][@bibr65-1470320316656679]--[@bibr66-1470320316656679]^ It is well known that the ACE2--angiotensin-(1-7)--Mas axis serves as the principal counter-regulatory mechanism for the ACE--angiotensin II--AT1 axis.^[@bibr67-1470320316656679]^ An increased ACE/ACE2 activity ratio might lead to increased angiotensin II generation and increased catabolism of angiotensin (1-7). Monotherapy with ACEIs could upregulate ACE2 expression to lower the risk of cancer.^[@bibr68-1470320316656679]^ These findings might explain the consistent findings in the observational studies included in this meta-analysis.

![Current view of the renin--angiotensin system cascade.](10.1177_1470320316656679-fig8){#fig8-1470320316656679}

The protection with RAS blockade against cancer in observational studies diminished in the pooled analysis of the RCTs. The difference in outcomes for cancer between the two types of studies is attributed to sample size and duration of follow-up ([Table 3](#table3-1470320316656679){ref-type="table"}). The 17 observational studies included in this meta-analysis provided a larger sample size than the 14 RCTs, and had a longer average duration of follow-up. Although observational studies have inherent limitations, which might compromise real associations between tested drugs and outcomes, it is difficult to implement RCTs in real clinical settings and lifetime treatment. In the present study, RCTs included in this analysis were not conducted to evaluate the effects of ARBs and ACEIs on the risk of cancer and cancer-related death as the primary endpoints. Concerning the differences in outcomes for cancer, here we have reported cancer incidence and mortality changes separately in RCTs and observational studies.

There are limitations in this study. First, the incidence and mortality of cancer were not the primary endpoints in some of the included case--control studies. Second, lack of the original data has prevented our direct evaluation of the effects of ARB/ACEI on different ethnic groups. Finally, the exact doses and dosages were inconsistent in the 31 studies included. All these limitations might affect the implication and interpretation of the findings from the present study.

In summary, the therapeutic benefits with ACEIs and ARBs reported in case--control studies and cohort studies might diminish in RCTs. The clinical design, site of cancer and duration of follow-up may affect the clinical outcomes.
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